Drug Profile
OCV C01
Alternative Names: C01; OCV-C01Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator OncoTherapy Science; Otsuka Pharmaceutical
- Developer OncoTherapy Science
- Class Cancer vaccines; Peptide vaccines; Peptides
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pancreatic cancer
Most Recent Events
- 23 Dec 2013 Discontinued - Phase-III for Pancreatic cancer (second-line therapy or greater) in Japan (SC)
- 29 Jul 2013 Phase-III development for Pancreatic Cancer (second-line therapy or greater) is ongoing in Japan (SC)
- 02 Nov 2012 Suspended - Phase-III for Pancreatic cancer (second-line therapy or greater) in Japan (SC)